Big Pharma Paradoxes (BPP): Selling simultaneously drugs which Induce and Treat melanomas: "The simple example for complicated Relations!"

Again we would like to focus the attention to a case of valsartan induced melanoma: a patient who has received two medical products (combined drug of amlodipine and valsartan 10/ 160mg (1-0-0), in the period 2008 to 2018, and additional valsartan 160mg (0-0-1) from 2015 that 1) the suspected primary melanocytic lesion was acquired one and occurred about three years after the start of the treatment with two different sartans 2) progression to cutaneous melanoma was observed when the dose of the valsartan was doubled within a period of 2,5 years, and 3) the exact application of the guidelines of AJCC for surgical treatment of cutaneous melanoma does not protect from melanoma progression (as in the case described by us) unlike the OSMS surgical model in which this progression is absent [3,4]. And what seems to be extraordinary is that 4) the progression of cutaneous melanoma to stage 4 was actually observed in a patient who was initially treated with two different sartans, produced from the same company that produces the Dabrafenib and Trametinib medication : the most widespread medications for treatment of melanoma at the moment [1]! Drugs, which have been subsequently used to treat ʺourʺ patient also?!